Intravitreal bevacizumab versus bevacizumab and 1 mg triamcinolone acetonide in eyes with bilateral diabetic macular edema

Basit Öğe Kaydı
dc.authorscopusid50263136900
dc.authorscopusid57197793503
dc.authorscopusid57208755790
dc.authorscopusid57208751427
dc.contributor.authorSever, Özkan
dc.contributor.authorHorozoğlu, Fatih
dc.contributor.authorÇelik, Erkan
dc.contributor.authorTopçu, Birol
dc.date.accessioned2022-05-11T14:13:59Z
dc.date.available2022-05-11T14:13:59Z
dc.date.issued2019
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalı
dc.departmentFakülteler, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Biyoistatistik Ana Bilim Dalı
dc.description.abstractAIM: To compare of intravitreal bevacizumab and intravitreal bevacizumab and triamcinolone acetonide in eyes with bilateral diabetic macular edema. METHODS: In this retrospective comparative-randomized study, 42 eyes of 21 diabetic patients with bilateral macular edema were evaluated. In one eye intravitreal injection of 1.25 mg bevacizumab (IVB group) was performed and in the fellow eye intravitreal injection of combined 1.25 mg bevacizumab and 1 mg triamcinolone acetonide (IVTA-IVB group) was performed. Main outcomes were the central macular thickness (CMT) measured with optical coherence tomography (OCT), ETDRS visual acuity (VA) and intraocular pressure (IOP). RESULTS: Mean follow-up time was 4.7±1.5mo. In the IVB and IVTA-IVB groups, mean CMT was 494.7±114.4 ?m and 546.8±165.6 ?m before injections; 430.4±133.2 ?m and 363.7±105.3 ?m in first month; 484.8±167.4 ?m and 407.3±108.7 ?m in 3rd month; 550.4±191.5 ?m and 516.8±158 ?m after 6mo respectively. Differences were significant in first and 3rd months (P<0.05). In the IVB and IVTA-IVB groups, mean ETDRS VA score was 57.1±13.5 and 48.9±13.9 before injections; 62.2±14 and 58.8±12.1 in first month; 59±13.7 and 59.3±13.6 in 3rd month; 55.6±14.9 and 55.5±8.7 after 6mo respectively. Differences were significant in first and 3rd and 6mo (P<0.05). There was no IOP difference. IVTA-IVB group gains best VA in 3rd month after the first injection and maintains it for 6mo whereas IVB group gains best VA at first month and can be able to maintain for 3mo. CONCLUSION: Injection of 1 mg IVTA-IVB seems to be better than IVB alone in improving VA for 6mo without any steroid dependent complications. Copyright 2019 by the IJO Press.
dc.identifier.doi10.3980/j.issn.1672-5123.2019.1.01
dc.identifier.endpage8
dc.identifier.issn1672-5123
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85065728663
dc.identifier.scopusqualityQ4
dc.identifier.startpage1
dc.identifier.urihttps://doi.org/10.3980/j.issn.1672-5123.2019.1.01
dc.identifier.urihttps://hdl.handle.net/20.500.11776/5728
dc.identifier.volume19
dc.indekslendigikaynakScopus
dc.institutionauthorSever, Özkan
dc.institutionauthorHorozoğlu, Fatih
dc.institutionauthorÇelik, Erkan
dc.institutionauthorTopçu, Birol
dc.language.isoen
dc.publisherInternational Journal of Ophthalmology (c/o Editorial Office)
dc.relation.ispartofInternational Eye Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBevacizumab
dc.subjectKEYWORDS:diabetic retinopathy
dc.subjectTriamcinolone acetonide
dc.subjectbevacizumab
dc.subjecthemoglobin A1c
dc.subjecttriamcinolone
dc.subjecttriamcinolone acetonide
dc.subjectadult
dc.subjectaged
dc.subjectartery perfusion
dc.subjectArticle
dc.subjectbilateral diabetic macular edema
dc.subjectcentral macular thickness
dc.subjectclinical article
dc.subjectclinical outcome
dc.subjectcombination drug therapy
dc.subjectcomparative study
dc.subjectcontrolled study
dc.subjectcornea limbus
dc.subjectdiabetes mellitus
dc.subjectdiabetic macular edema
dc.subjectdiabetic patient
dc.subjectdisease duration
dc.subjectfemale
dc.subjectfollow up
dc.subjecthemoglobin blood level
dc.subjecthuman
dc.subjecthypertension
dc.subjectintraocular pressure
dc.subjectlaser coagulation
dc.subjectmale
dc.subjectmonotherapy
dc.subjectoculoplethysmography
dc.subjectophthalmoscopy
dc.subjectpanretinal photocoagulation
dc.subjectproliferative diabetic retinopathy
dc.subjectretina artery
dc.subjectretrospective study
dc.subjectvisual acuity
dc.titleIntravitreal bevacizumab versus bevacizumab and 1 mg triamcinolone acetonide in eyes with bilateral diabetic macular edema
dc.title.alternative????????????????????????????]
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu